Dear All, I wonder if anyone can answer a query that I can't seem to find an adequate answer to in my literature searches. There is much talk about analysing the patterns of B and T cell maturation for abnormalities as markers of minimal residual disease, in B cell precursor and T cell ALL respectively. What about in AML? Other than analysing for aberrant phenotypes, what patterns are people looking at in follow up samples as markers of residual disease? I have read about abnormal patterns of CD34+ cells, but have not been able to find any details of what precisely people are doing. Can anyone help? Thanks in anticipation. Sarah Lawson (isaac.lawson@btinternet.com)
This archive was generated by hypermail 2b29 : Sat Mar 10 2001 - 19:31:08 EST